Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Function and Metabolism in Type 2 DM Patients at high cardiovascular risk: The SIMPle Randomized Clinical Trial.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Jul 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Empagliflozin (Primary)
Indications Cardiovascular disorders; Heart failure; Myocardial infarction; Peripheral arterial disorders; Stroke; Type 2 diabetes mellitus
Focus Pharmacodynamics
Acronyms SIMPLE

01 Mar 2022 Results investigating the effects of 13 weeks treatment with empagliflozin in patients with high-risk type-2 diabetes mellitus on echocardiographic measures of left ventricular structure and function, published in the International Journal of Cardiovascular Imaging
09 Jul 2020 Status changed from active, no longer recruiting to completed.
26 Jun 2020 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com